DGAP-News

Oxford Immunotec Schedules Second Quarter 2014 Earnings Release and Conference Call for August 5, 2014

DGAP-News: Oxford Immunotec /
Oxford Immunotec Schedules Second Quarter 2014 Earnings Release and
Conference Call for August 5, 2014

23.07.2014 / 15:59

---------------------------------------------------------------------

OXFORD, United Kingdom and MARLBOROUGH, Mass., 2014-07-23 16:00 CEST (GLOBE
NEWSWIRE) --
Oxford Immunotec Global PLC (Nasdaq:OXFD) today announced that it plans to
release second quarter 2014 financial results prior to market open on Tuesday,
August 5, 2014. Dr. Peter Wrighton-Smith, Chief Executive Officer, and Rick
Altieri, Chief Financial Officer, will host a conference call to review the
Company's results at 8:00 a.m. Eastern Time the same day. The call will be
concurrently webcast.

To listen to the conference call on your telephone please dial [phone]
for United States callers and [phone] for international callers and
reference confirmation code 77008170, approximately ten minutes prior to start
time. To access the live audio webcast or subsequent archived recording, visit
the Investor Relations section of Oxford Immunotec's website at
http://www.oxfordimmunotec.com. The replay will be available on the Company's
website for approximately 90 days.

Notes to Editors:

About Oxford Immunotec Global PLC

Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company
committed to improving patient care by providing advanced, innovative tests in
the field of immunology. The proprietary T-SPOT(r) technology platform measures
the responses of specific immune cells, known as T cells, to inform the
diagnosis, prognosis and monitoring of patients with immunologically controlled
diseases. T cells are a central component of the human body's immune system,
and are implicated in the control and progression of many medical conditions,
including certain types of infectious diseases, cancers and autoimmune
diseases. The Company's initial product developed using the T-SPOT technology
platform is the T-SPOT(r).TB test, which is used to test for latent tuberculosis
infection. The T-SPOT.TB test has been approved for sale in over 50 countries,
including the United States, where it has received pre-market approval from the
Food and Drug Administration, Europe, where it has obtained a CE mark, as well
as Japan and China. The Company is headquartered near Oxford, UK and in
Marlborough, MA.

Additional information can be found at www.oxfordimmunotec.com.

T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd.

Forward-Looking Statements

This release contains forward-looking statements, including statements
regarding future success of the company. These forward-looking statements are
subject to risks and uncertainties that could cause actual results to differ
materially. Forward-looking statements are based on current expectations and
assumptions and currently available data and are neither predictions nor
guarantees of future events or performance. You should not place undue reliance
on forward-looking statements, which speak only as of the date of this
presentation. We do not undertake to update or revise any forward-looking
statements after they are made, whether as a result of new information, future
events, or otherwise, except as required by applicable law.

CONTACTS:

For Media Inquiries:
Caroline Crawley
Oxford Immunotec
Tel: [phone]
[e-mail]

For Investor Inquiries:
Rick Altieri
Chief Financial Officer,
Oxford Immunotec
Tel: [phone]
[e-mail]

Mark Klausner
Westwicke Partners
Tel: [phone]
[e-mail]
News Source: NASDAQ OMX


End of Corporate News

---------------------------------------------------------------------

23.07.2014 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


Language: English
Company: Oxford Immunotec


United Kingdom
ISIN: GB00BGFBB958


End of News DGAP News-Service
---------------------------------------------------------------------
279055 23.07.2014